Biophytis S.A. (BPTS)
| Market Cap | 8.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.76M |
| Shares Out | 5.62M |
| EPS (ttm) | -14.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,965,994 |
| Open | 1.24 |
| Previous Close | 0.88 |
| Day's Range | 1.04 - 2.06 |
| 52-Week Range | 0.88 - 9.02 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+843.4%) |
| Earnings Date | Apr 18, 2023 |
About BPTS
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is... [Read more]
Analyst Forecast
According to one analyst, the rating for BPTS stock is "Strong Buy" and the 12-month stock price forecast is $15.0.
News
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the d...
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the d...
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the d...
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 11,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the ...
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company sp...
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project
PARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / August 16, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the dev...
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the devel...
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the deve...
Biophytis Announces $3.8 Million Registered Direct Offering
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / July 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused ...
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
PARIS, FRANCE / ACCESSWIRE / July 18, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutic...
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 10, 2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company special...
Biophytis Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / June 19, 2023 / Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), («Biophytis» or the «company»), a clinical-stage biotechnology company focuse...
Biophytis: Results of the Annual General Meeting on June 16, 2023 All Resolutions Presented by the Company Have Been Adopted
RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED PARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 16, 2023 / Biophytis SA (NASDAQ:BPT...
Biophytis to Participate at the BIO International Convention in Boston from the 5th to the 8th of June
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / June 5, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 26, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on ...
Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 25, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on ...
Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 15, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on ...
Successful Capital Increase for Biophytis with €2.3 million Raised
Success of the placement with professional investors, historical supporters of the Company, for an amount of €1.9M. Strong participation of retail investors via the PrimaryBid platform with an offer a...
Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros
Capital increases as part of a global offering comprising an offer reserved for professional investors and a public offering for retail investors through the PrimaryBid platform. The PrimaryBid offeri...
Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 9, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on...
Biophytis Strengthens its Management Team
Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality Assurance Appointment of Nicolas Fellmann as Chief Financial Officer PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWORE / ...
Biophytis Announces Receipt of Nasdaq Notice
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 28, 2023 / Biophytis SA (NasdaqCM:BPTS), (Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focus...
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused o...
Biophytis Announces 2022 Financial Results and 2023 Perspectives
€11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 Positive results of the Phase 2-3 COVA study ...
Biophytis: Results of the Combined General Meeting on April 17, 2023
Adoption of all resolutions Reduction of the nominal value of the share to 0.01 euro PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2022 / Biophytis SA (Nasdaq CM :BPTS)(Euronext Growth Pari...